| Title | Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders. | | Author(s) | McDougle CJ, Stigler KA, Erickson CA, Posey DJ | | Institution | Department of Psychiatry, Indiana University School of Medicine, Christian Sarkine Autism Treatment Center, James Whitcomb Riley Hospital for Children, Indianapolis, IN 46202-4800, USA. cmcdougl@iupui.edu | | Source | J Clin Psychiatry 2008.:15-20. | | MeSH | Adolescent
Aggression
Antipsychotic Agents
Autistic Disorder
Benzodiazepines
Child
Child Development Disorders, Pervasive
Child, Preschool
Clozapine
Dibenzothiazepines
Disorders of Excessive Somnolence
Humans
Obesity
Piperazines
Quinolones
Risperidone
Thiazoles
| | Abstract | Atypical antipsychotics are emerging as the first-line pharmacologic treatment for irritability (i.e., aggression, self-injurious behavior, and severe tantrums) in children and adolescents with autistic and other pervasive developmental disorders. Results from placebo-controlled and open-label studies of clozapine, risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole in this subject population are reviewed. Additional placebo-controlled trials and studies of longer-term safety and tolerability are needed. | | Language | eng | | Pub Type(s) | Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review
| | PubMed ID | 18533764 |
|
